2+ day, 8+ hour ago   (139+ words) The Dermatology Digest Fieldmaxxing: Maximizing Field Therapy for AK With Dr. Vishal Patel Tanmaxxing is on trend, but off the mark, and it can increase risks of both visible and beneath-the- surface skin damage, explains Vishal Anil Patel, MD, FASDS,…...

1+ mon, 1+ week ago   (242+ words) Ritlecitinib (Litfulo, Pfizer) is showing promise in nonsegmental vitiligo, according to positive topline results from two Phase 3 trials, The TRANQUILLO study included patients aged 12 years and up, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50mg and 100mg doses of…...

1+ mon, 2+ week ago   (142+ words) The Dermatology Digest Health Canada Approves Remibrutinib for CSU Health Canada has issued a Notice of Compliance (NOC) for remibrutinib (Rhapsido, Novartis) for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. A…...

1+ mon, 3+ week ago   (538+ words) The Dermatology Digest SKNV Secures Exclusive Commercialization Rights for Kefunova Cream SKNV now has exclusive commercialization rights to the patent portfolio owned by Washington University in St. Louis, covering the combination of Fluorouracil and Calcipotriene therapies, which is currently available…...

1+ mon, 4+ week ago   (112+ words) HBI-8000 in combination with nivolumab (Opdivo, BMS) met its primary endpoint in a Phase 3 trial of patients with advanced melanoma, according to topline results reported by HUYABIO International. Patients receiving HBI-8000 plus nivolumab achieved a median progression-free survival of 11.7 months,…...

2+ mon, 3+ day ago   (292+ words) Tralokinumab’s (Adbry, Adtralza, LEO PHARMA) pharmacokinetic profile was consistent with what has previously been observed and generally well tolerated for up to 172 weeks of treatment, with no new safety signals in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD),…...

2+ mon, 1+ week ago   (356+ words) The Dermatology Digest Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development Evommune, Inc.’s Phase 2b trial of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU) did not meet the primary endpoint of mean change in…...

3+ mon, 10+ hour ago   (356+ words) The Dermatology Digest Will Remibrutinib Become the First-ever Approved Drug for CIndU? Remibrutinib (Rhapsido, Novartis) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes—symptomatic dermographism (SD), cold urticaria, and cholinergic urticaria, according to results…...

3+ mon, 1+ day ago   (192+ words) The Dermatology Digest Takeda’s Oral TYK2 Bests Deucravacitinib in Head-to-Head Phase 3 PsO Study Zasocitinib (TAK-279, Takeda), an investigational, next-generation oral tyrosine kinase 2 (TYK2) inhibitor bested deucravacitinib (Sotyktu, BMZ(in adults with moderate-to-severe plaque psoriasis, according to positive topline results from a Phase…...

3+ mon, 1+ week ago   (262+ words) As many as 75% of psoriasis patients who respond well to interleukin (IL)-17 and IL-23 inhibitors can safely reduce their dosage, often even by half, finds a new study in The Lancet Regional Health – Europe. “These medicines are life-changing’, says Elke de Jong,…...